A Study of LY2951742 in Participants With Migraine
Status:
Completed
Trial end date:
2013-09-18
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of LY2951742 in the prevention of migraine headache in
migraineurs with or without aura during 3 months of treatment.